New Bioactive Compound for Difficult-to-Treat Allergies

Study leads to the discovery of a promising receptor blocker

02-May-2025 - Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response—which in severe cases can be life-threatening. A team of researchers led by the University of Bonn has now ...

Medication that hits the mark

26-Mar-2025 - We want drugs to have an increasingly specific effect. Targeted drug delivery is one promising route – it involves the targeted release of active ingredients at their destination in order to minimize side effects. A Vienna-based research team has developed a method that enables them to precisely ...

New numbering system facilitates comparability of protein domains

Researchers analyse models using AI

30-Jan-2025 - Adhesion GPCRs are a group of cell-surface sensors associated with many body functions and diseases. However, they are not yet sufficiently understood to be exploited for therapies. Collaborative Research Centre (CRC) 1423 at Leipzig University aims to change this. Scientists at the Faculty of ...

Advance in pain relief research

Naturally occurring hederagenin binds to pain regulation receptor

13-Dec-2024 - A team of scientists led by Professor Annette Beck-Sickinger from the Institute of Biochemistry at Leipzig University has made an important advance in pain relief research. They discovered that hederagenin, a naturally occurring substance found in the medicinal plant ivy, binds to the pain ...

How Immune Cells “Sniff Out” Pathogens

Researchers are using an innovative method to watch immune receptors go about their business

19-Nov-2024 - Immune cells are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. But what signals activate TLRs, and what is the relationship between the scale and nature of this activation and the substance being detected? In a ...

Generative AI antibody design platform

Antiverse raises £3.5M

21-Oct-2024 - Antiverse, a techbio company designing antibodies for challenging targets, announced it has added £3.5M ($4.6M) to its seed funding. The investment will facilitate the Company’s growth, including appointments to strengthen the team and continued development of its antibody design programmes, many ...

What triggers the programmed cell death mechanism?

Development and combination of various microscopic and spectroscopic techniques

13-Sep-2024 - How can molecular structures be analysed when the resolution of the techniques available is not sufficient? Researchers from the fields of physics, chemistry and medicine at Heinrich Heine University Düsseldorf (HHU) have combined and further developed various microscopic and spectroscopic ...

A new drug target for psychiatric disorders

11-Sep-2024 - Misha Kudryashev’s lab at the Max Delbrück Center has identified a molecular intermediate of a serotonin receptor that is involved in diseases such as depression and schizophrenia. The study points to a potentially new target for therapeutics. A new study published in “The EMBO Journal” points ...

Light switch for special receptors

IMC Krems plays a leading role in the establishment of innovative cell-based test systems for the identification of biomarkers.

16-Aug-2024 - A research project led by the IMC University of Applied Sciences Krems has just been successfully completed and now provides an excellent basis for further projects: Prof. Christoph Wiesner's team from the Institute of Biotechnology succeeded in genetically modifying special receptors (Toll-like ...

Confo Therapeutics Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies into Clinical Development

Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval

06-Aug-2024 - Confo Therapeutics announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management and Quest for Growth (QfG), as well as existing investors, BioGeneration Ventures ...